ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
UCB SA

UCB SA (UCB)

186,60
1,80
(0,97%)
Geschlossen 20 Dezember 5:30PM

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Wichtige Statistiken und Details

Current Price
186,60
Gebot
183,70
Fragen
187,00
Volumen
540.704
179,20 Tagesbereich 186,60
75,86 52-Wochen-Bereich 190,20
Marktkapitalisierung
Handelsende
184,80
Handelsbeginn
183,90
Letzte Trade
235
@
186.6
Letzter Handelszeitpunkt
Finanzvolumen
-
VWAP
-
Durchschnittliches Volumen (3 Mio.)
212.883
Ausgegebene Aktien
194.506.000
Dividendenrendite
-
Kurs-Gewinn-Verhältnis
105,82
Gewinn pro Aktie (EPS)
1,76
Erlöse
4,87B
Nettogewinn
343M

Über UCB SA

Sektor
Pharmaceutical Preparations
Branche
Chemicals & Allied Products
Website
Hauptsitz
Brussels, Brussels-capital Region, Bel
Gegründet
1928
UCB SA is listed in the Pharmaceutical Preparations sector of the Euronext with ticker UCB. The last closing price for UCB was 184,80 €. Over the last year, UCB shares have traded in a share price range of 75,86 € to 190,20 €.

UCB currently has 194.506.000 shares in issue. The market capitalisation of UCB is 35,94 € billion. UCB has a price to earnings ratio (PE ratio) of 105.82.

UCB Neueste Nachrichten

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity

Dapirolizumab pegol (DZP) met its primary endpoint, demonstrating statistically and clinically significant improvement across all organ systems as measured by BICLA, an endpoint measuring disease...

UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024

Phase 3 PHOENYCS GO study met the primary endpoint demonstrating clinical improvement in moderate-to-severe systemic lupus erythematosus; Clinical improvements were observed among key secondary...

UCB Convening Notice to the General Meeting of the Shareholders 2024

UCB Convening Notice to the General Meeting of the Shareholders 2024 CONVENING NOTICE TO THE GENERAL MEETING OF SHAREHOLDERS The Board of Directors invites the shareholders for the ordinary...

ClearPoint Neuro and UCB Enter License Agreement for Gene Therapy Drug Delivery

SOLANA BEACH, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) a global therapy-enabling platform company providing navigation and delivery to the brain, today...

UCB Convocation à L’ Assemblée Générale des Actionnaires 2023

UCB Convocation à L’ Assemblée Générale des Actionnaires 2023 CONVOCATION A L’ASSEMBLEE GENERALE DES ACTIONNAIRES Le Conseil d’Administration invite les actionnaires à l’assemblée générale...

Praxis Precision Medicines and UCB Announce Epilepsy Research Collaboration

BOSTON, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company, and UCB (EURONEXT BRUSSELS: UCB), a global...

UCB SA - CONVOCATION A L’ASSEMBLEE GENERALE DES ACTIONNAIRES 2022

UCB SA - CONVOCATION A L’ASSEMBLEE GENERALE DES ACTIONNAIRES 2022 UCB -Société AnonymeAllée de la Recherche 60, 1070 Bruxellesn° d’entreprise 0403.053.608 (RPM Bruxelles)www.ucb.com(« UCB...

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
15.93.2650802435180.7187.55178.8177280185.1835395DE
411.66.62857142857175190.2175203740183.98430038DE
1223.8514.6543778802162.75190.2160.3212883176.71473256DE
2648.535.1194786387138.1190.2133.95217059162.59385673DE
52110143.60313315976.6190.275.86255107131.86044026DE
15690.1493.448061372696.46190.265.427009097.75458005DE
260113.68155.89687328672.92190.260.1829124494.21423855DE

UCB - Frequently Asked Questions (FAQ)

What is the current UCB share price?
The current share price of UCB is 186,60 €
How many UCB shares are in issue?
UCB has 194.506.000 shares in issue
What is the market cap of UCB?
The market capitalisation of UCB is EUR 35,94B
What is the 1 year trading range for UCB share price?
UCB has traded in the range of 75,86 € to 190,20 € during the past year
What is the PE ratio of UCB?
The price to earnings ratio of UCB is 105,82
What is the cash to sales ratio of UCB?
The cash to sales ratio of UCB is 7,46
What is the reporting currency for UCB?
UCB reports financial results in EUR
What is the latest annual turnover for UCB?
The latest annual turnover of UCB is EUR 4,87B
What is the latest annual profit for UCB?
The latest annual profit of UCB is EUR 343M
What is the registered address of UCB?
The registered address for UCB is 60, ALLEE DE LA RECHERCHE, BRUSSELS, BRUSSELS-CAPITAL REGION, B-1070
What is the UCB website address?
The website address for UCB is www.ucb.com
Which industry sector does UCB operate in?
UCB operates in the CHEMICALS & ALLIED PRODUCTS sector
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
TMBSZTME Pharma NV
0,02 €
(185,71%)
132,5k
MLGEQGentlemen S Equity SA
0,0175 €
(118,75%)
1,14k
ALCYBCybergun
0,0002 €
(100,00%)
17,54M
MLAAHAmatheon Agri Holding NV
0,0185 €
(54,17%)
40,1k
ALARFAdeunis
0,94 €
(28,77%)
5,27k
MLSMLSmalto
0,0125 €
(-37,50%)
2,34k
MLFTIFrance Tourisme Immobilier
0,025 €
(-35,90%)
56,77k
CNVCnova NV
0,209 €
(-19,62%)
26,38k
MLWEAWeaccess Group
0,382 €
(-16,96%)
5,95k
ALEUPEuroplasma
0,0353 €
(-15,95%)
3,16M
ATOAtos SE
0,0021 €
(0,00%)
2,71B
BCPBanco Comercial Portugues SA
0,4493 €
(-0,69%)
66,54M
ALHGLouis Hachette Group
1,3342 €
(4,87%)
52,04M
KPNKoninklijke KPN NV
3,509 €
(-1,21%)
26,9M
VIVVivendi SE
2,51 €
(2,41%)
26,39M
Keine Diskussionen Gefunden.
Neuen Thread Erstellen

Kürzlich von Ihnen besucht

Delayed Upgrade Clock